查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797995

2032 年神经调节设备市场预测：按产品类型、适应症、MRI 相容性、生医材料、最终用户和地区进行的全球分析

Neuromodulation Devices Market Forecasts to 2032 - Global Analysis By Product Type, Indication, MRI Compatibility, Biomaterial, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球神经调节设备市场预计在 2025 年达到 22 亿美元，到 2032 年将达到 120 亿美元，预测期内的复合年增长率为 5.0%。

神经调节装置是一种医疗技术，旨在透过向特定神经或神经部位传递定向刺激（例如电脉衝或化学药剂）来改变神经活动。这些装置通常用于纠正异常神经讯号，以恢復或使神经系统功能正常化，并缓解慢性疼痛、运动障碍和神经功能障碍等症状。刺激透过调节神经兴奋性和通路，直接影响神经传递，进而产生治疗效果。

根据美国癫痫基金会和世界卫生组织 (WHO) 的数据，全球约有 5,000 万人患有癫痫。

慢性神经系统疾病的增加

帕金森氏症、癫痫、阿兹海默症和慢性疼痛症候群等神经系统疾病的盛行率不断上升，是神经调节设备市场的主要驱动力。人口老化和生活方式相关併发症的增多，推动了对微创、长期治疗方案的需求。神经调节设备提供有针对性的、可逆的、可程式设计的治疗方案，使其成为一种颇具吸引力的药物替代方案。神经系统疾病负担的日益加重，促使医疗保健系统和从业人员采用此类创新治疗方法。

神经调节剂高成本

神经调节装置相关的高昂成本（包括植入、维护和编程）构成了其广泛应用的重大障碍。高昂的初始投资，加上某些地区的报销额度有限，限制了其普及，尤其是在中低收入国家。此外，后续观察、电池更换和设备相关服务进一步增加了长期治疗成本。这些经济限制限制了严重患者的应用，并延误了缺乏足够保险或政府支持的患者的治疗。

神经调节疗法的认知度和接受度不断提高

人们对非药物疼痛和神经系统治疗的认识日益加深，使得患者和医护人员对神经调节疗法的接受度不断提高。教育宣传活动、临床成功案例以及不断扩展的临床证据增强了人们对基于设备的治疗方法的信心。此外，个人化医疗和精准医疗的转变也增强了神经调节疗法的吸引力。随着围绕植入式设备的污名逐渐消退，以及该技术越来越普及，新的患者群体正在进入市场，尤其是在先前缺乏先进神经介入疗法服务的地区。

设备相关併发症和副作用的风险

感染疾病、导线移位、硬体故障以及刺激相关副作用等潜在风险仍令人担忧，威胁市场扩张。这些併发症可能导致设备再次手术或移除，增加患者不适感和治疗成本。此外，对手术植入、长期依赖性以及对其他身体系统的潜在干扰的担忧，也令患者和医生感到沮丧。负面结果和备受瞩目的产品召回也可能影响大众对神经调节技术的信任。

COVID-19的影响：

由于封锁措施以及资源向重症监护的重新分配，COVID-19 疫情最初扰乱了择期神经调节手术。许多患者推迟了手术，导致销售额和植入数量在短期内下降。然而，疫情后的復苏得益于对慢性病管理的重新关注以及门诊治疗需求的增加。远端医疗和远端设备编程解决方案也已成为宝贵的工具，确保了护理的连续性，并重塑了神经调节领域的服务交付模式。

脊髓刺激设备市场预计将成为预测期内最大的市场

预计脊髓刺激设备细分市场将在预测期内占据最大市场占有率，这主要得益于慢性腰腿痛的高发生率。这些装置广泛用于治疗腰椎手术失败综合征和复杂性局部疼痛症候群，并已证明其长期疗效。闭合迴路系统和无线编程等持续的产品创新正在改善治疗效果和患者依从性。此外，主要市场的优惠报销政策也进一步推动了脊髓刺激设备的大规模应用。

深层脑部刺激器领域预计将在预测期内实现最高复合年增长率

预计深层脑部刺激器领域将在预测期内呈现最高成长率，这得益于对治疗帕金森氏症、肌张力不全症和自发性震颤等先进疗法的需求不断增长。精准定位和程式灵活性方面的技术进步正在改善患者的治疗效果。此外，在忧郁症和强迫性精神官能症精神疾病和神经精神疾病应用方面的研究日益增多，也正在扩大深部脑部刺激的应用范围。随着临床适应症的扩展，该领域有望加速全球成长。

比最大的地区

预计亚太地区将在预测期内占据最大市场占有率，这得益于神经系统疾病盛行率上升、医疗支出增加以及先进医疗技术日益普及等因素。中国、日本和印度等国家正在大力投资神经病学基础设施和基于设备的治疗。此外，患者意识的增强、私人医疗网络的扩张以及政府在神经復健领域的扶持政策正在推动区域需求。庞大的人口规模和日益加速的都市化进一步巩固了亚太地区在神经调节设备市场的主导地位。

复合年增长率最高的地区：

预计北美地区在预测期内将实现最高的复合年增长率，这得益于神经病变率的上升、医疗保健支出的增加以及先进医疗技术的普及。中国、日本和印度等国家正在大力投资神经病学基础设施和基于设备的疗法。此外，患者意识的增强、私人医疗网络的扩张以及政府对神经復健的支持也推动了区域需求。庞大的人口和日益加速的都市化进一步巩固了亚太地区在神经调节设备市场的主导地位。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球神经调节设备市场（依产品类型）

  • 脊髓刺激设备
  • 深层脑部刺激器
  • 荐骨神经刺激器
  • 迷走神经刺激设备
  • 经颅磁刺激仪
  • 其他产品类型

6. 全球神经调节设备市场（按适应症）

  • 慢性疼痛
  • 肌张力不全症
  • 癫痫
  • 自发性震颤
  • 心臟衰竭
  • 重度忧郁症
  • 帕金森氏症
  • 强迫性精神官能症
  • 膀胱过动症
  • 睡眠呼吸中止症

7. 全球神经调节设备市场：MRI 相容性

  • MRI相容
  • MRI 不相容

8. 全球神经调节设备市场（依生医材料）

  • 金属生医材料
  • 聚合物生医材料
  • 陶瓷生医材料

9. 全球神经调节设备市场（依最终用户）

  • 医院
  • 神经科诊所
  • 家庭医疗保健

第十章全球神经调节设备市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Medtronic
  • Boston Scientific Corporation
  • Stryker
  • Abbott
  • B. Braun Melsungen AG
  • NEVRO CORP.
  • NeuroSigma, Inc
  • NeuroPace, Inc.
  • Soterix Medical Inc
  • Synapse Biomedical Inc
  • ReShape Lifesciences, Inc
  • Bioness Inc.
  • ALEVA NEUROTHERAPEUTICS SA
  • LivaNova PLC
  • Neuronetics
  • Cyberonics, Inc.
  • Neuromod
  • Axonics, Inc.
Product Code: SMRC30365

According to Stratistics MRC, the Global Neuromodulation Devices Market is accounted for $2.2 billion in 2025 and is expected to reach $12.0 billion by 2032 growing at a CAGR of 5.0% during the forecast period. Neuromodulation devices are medical technologies designed to alter nerve activity by delivering targeted stimuli, such as electrical impulses or chemical agents, to specific nerves or neurological sites. These devices modify abnormal nerve signals to restore or normalize nervous system functions, often used to relieve symptoms like chronic pain, movement disorders, or neurological dysfunctions. The stimulation can adjust nerve excitability or pathways, providing therapeutic effects by influencing nerve communication directly.

According to the Epilepsy Foundation of America and World Health Organization (WHO), an estimated 50 million people globally were suffering from epilepsy.

Market Dynamics:

Driver:

Increasing prevalence of chronic neurological diseases

The growing incidence of neurological disorders such as Parkinson's disease, epilepsy, Alzheimer's, and chronic pain syndromes is a key driver for the neuromodulation devices market. With aging populations and lifestyle-related complications on the rise, demand for minimally invasive, long-term therapeutic solutions is increasing. Neuromodulation devices offer targeted, reversible, and programmable therapy, making them attractive alternatives to pharmaceuticals. The rising burden of neurological conditions is pushing healthcare systems and practitioners to adopt these innovative treatment modalities.

Restraint:

High cost of neuromodulation devices

The significant cost associated with neuromodulation devices, including implantation, maintenance, and programming, poses a major barrier to widespread adoption. High initial investment, coupled with limited reimbursement coverage in several regions, restricts access, especially in low- and middle-income countries. Additionally, follow-up visits, battery replacements, and device-related services further inflate long-term treatment costs. These economic limitations discourage adoption in non-critical cases and delay therapy for patients without sufficient insurance or government support.

Opportunity:

Growing awareness and acceptance of neuromodulation therapies

Increased awareness of non-pharmacological pain and neurological treatments has led to rising acceptance of neuromodulation therapies across both patients and healthcare providers. Educational campaigns, clinical success stories, and expanding clinical evidence are building trust in device-based therapies. Furthermore, the shift toward personalized and precision medicine supports neuromodulation's appeal. As stigma around implantable devices decreases and technology becomes more accessible, new patient demographics are entering the market, especially in regions previously underserved by advanced neuro-interventions.

Threat:

Risk of device-associated complications and side effects

Potential risks such as infections, lead migration, hardware malfunction, and stimulation-related side effects remain concerns that threaten the market's expansion. These complications may lead to device revision or explantation, increasing patient discomfort and treatment costs. Moreover, apprehensions about surgical implantation, long-term dependence, and possible interference with other bodily systems can deter both patients and physicians. Negative outcomes or high-profile product recalls could also impact public confidence in neuromodulation technologies.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted elective neuromodulation procedures due to lockdowns and resource reallocation toward critical care. Many patients delayed surgeries, leading to short-term declines in sales and implant volumes. However, post-pandemic recovery has been fueled by a renewed focus on chronic condition management and growing demand for outpatient-based treatments. Telehealth and remote device programming solutions also emerged as valuable tools, ensuring continuity of care and reshaping service delivery models in the neuromodulation sector.

The spinal cord stimulators segment is expected to be the largest during the forecast period

The spinal cord stimulators segment is expected to account for the largest market share during the forecast period propelled by the high prevalence of chronic back and leg pain disorders. These devices are widely used in treating failed back surgery syndrome and complex regional pain syndrome, with proven long-term efficacy. Continuous product innovations, such as closed-loop systems and wireless programming, enhance treatment outcomes and patient compliance. Moreover, favorable reimbursement policies in key markets further support the large-scale adoption of spinal cord stimulators.

The deep brain stimulators segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep brain stimulators segment is predicted to witness the highest growth rate, influenced by increasing demand for advanced therapies in managing Parkinson's disease, dystonia, and essential tremor. Technological advancements in targeting precision and programming flexibility are improving patient outcomes. Furthermore, growing research in psychiatric and neuropsychiatric applications, including depression and OCD, is expanding the scope of deep brain stimulation. As clinical indications widen, the segment is positioned for accelerated global growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, fuelled by, rising neurological disorder prevalence, growing healthcare expenditure, and increasing adoption of advanced medical technologies. Countries like China, Japan, and India are investing heavily in neurology infrastructure and device-based therapies. Moreover, growing patient awareness, expanding private healthcare networks, and supportive government initiatives in neurorehabilitation drive regional demand. The large population base and ongoing urbanization further strengthen Asia Pacific's dominance in the neuromodulation devices market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by, rising neurological disorder prevalence, growing healthcare expenditure, and increasing adoption of advanced medical technologies. Countries like China, Japan, and India are investing heavily in neurology infrastructure and device-based therapies. Moreover, growing patient awareness, expanding private healthcare networks, and supportive government initiatives in neurorehabilitation drive regional demand. The large population base and ongoing urbanization further strengthen Asia Pacific's dominance in the neuromodulation devices market.

Key players in the market

Some of the key players in Neuromodulation Devices Market include Medtronic, Boston Scientific Corporation, Stryker, Abbott, B. Braun Melsungen AG, NEVRO CORP., NeuroSigma, Inc, NeuroPace, Inc., Soterix Medical Inc, Synapse Biomedical Inc, ReShape Lifesciences, Inc, Bioness Inc., ALEVA NEUROTHERAPEUTICS SA, LivaNova PLC, Neuronetics, Cyberonics, Inc., Neuromod, and Axonics, Inc.

Key Developments:

In July 2025, Boston Scientific received FDA approval for two new SCS leads-Linear 3-4 and Linear 3-6-for its Precision Plus SCS System, expanding percutaneous lead configuration options in the market.

In April 2025, Abbott introduced a next-generation delivery system for its Proclaim(TM) DRG neurostimulation-the first FDA-approved DRG technology for treating complex regional pain syndrome (CRPS) types 1 & 2-designed to streamline electrode placement to the dorsal root ganglion.

In January 2025, Medtronic achieved CE mark approval for its BrainSense Adaptive Deep Brain Stimulation (aDBS) and Electrode Identifier systems-a significant milestone enabling personalized, sensing-enabled care for Parkinson's patients in Europe.

Product Types Covered:

  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Transcranial Magnetic Stimulators
  • Other Product Types

Indications Covered:

  • Chronic Pain
  • Dystonia
  • Epilepsy
  • Essential Tremor
  • Heart Failure
  • Major Depressive Disorder
  • Parkinson's Disease
  • Obsessive-Compulsive Disorder
  • Overactive Bladder
  • Sleep Apnea

MRI Compatibilities Covered:

  • MRI Compatible
  • MRI Non-Compatible

Biomaterials Covered:

  • Metallic Biomaterials
  • Polymeric Biomaterials
  • Ceramic Biomaterials

End Users Covered:

  • Hospital
  • Neurological Clinics
  • Home Healthcare

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuromodulation Devices Market, By Product Type

  • 5.1 Introduction
  • 5.2 Spinal Cord Stimulators
  • 5.3 Deep Brain Stimulators
  • 5.4 Sacral Nerve Stimulators
  • 5.5 Vagus Nerve Stimulators
  • 5.6 Transcranial Magnetic Stimulators
  • 5.7 Other Product Types

6 Global Neuromodulation Devices Market, By Indication

  • 6.1 Introduction
  • 6.2 Chronic Pain
  • 6.3 Dystonia
  • 6.4 Epilepsy
  • 6.5 Essential Tremor
  • 6.6 Heart Failure
  • 6.7 Major Depressive Disorder
  • 6.8 Parkinson's Disease
  • 6.9 Obsessive-Compulsive Disorder
  • 6.10 Overactive Bladder
  • 6.11 Sleep Apnea

7 Global Neuromodulation Devices Market, By MRI Compatibility

  • 7.1 Introduction
  • 7.2 MRI Compatible
  • 7.3 MRI Non-Compatible

8 Global Neuromodulation Devices Market, By Biomaterial

  • 8.1 Introduction
  • 8.2 Metallic Biomaterials
  • 8.3 Polymeric Biomaterials
  • 8.4 Ceramic Biomaterials

9 Global Neuromodulation Devices Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital
  • 9.3 Neurological Clinics
  • 9.4 Home Healthcare

10 Global Neuromodulation Devices Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Medtronic
  • 12.2 Boston Scientific Corporation
  • 12.3 Stryker
  • 12.4 Abbott
  • 12.5 B. Braun Melsungen AG
  • 12.6 NEVRO CORP.
  • 12.7 NeuroSigma, Inc
  • 12.8 NeuroPace, Inc.
  • 12.9 Soterix Medical Inc
  • 12.10 Synapse Biomedical Inc
  • 12.11 ReShape Lifesciences, Inc
  • 12.12 Bioness Inc.
  • 12.13 ALEVA NEUROTHERAPEUTICS SA
  • 12.14 LivaNova PLC
  • 12.15 Neuronetics
  • 12.16 Cyberonics, Inc.
  • 12.17 Neuromod
  • 12.18 Axonics, Inc.

List of Tables

  • Table 1 Global Neuromodulation Devices Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Neuromodulation Devices Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Neuromodulation Devices Market Outlook, By Spinal Cord Stimulators (2024-2032) ($MN)
  • Table 4 Global Neuromodulation Devices Market Outlook, By Deep Brain Stimulators (2024-2032) ($MN)
  • Table 5 Global Neuromodulation Devices Market Outlook, By Sacral Nerve Stimulators (2024-2032) ($MN)
  • Table 6 Global Neuromodulation Devices Market Outlook, By Vagus Nerve Stimulators (2024-2032) ($MN)
  • Table 7 Global Neuromodulation Devices Market Outlook, By Transcranial Magnetic Stimulators (2024-2032) ($MN)
  • Table 8 Global Neuromodulation Devices Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 9 Global Neuromodulation Devices Market Outlook, By Indication (2024-2032) ($MN)
  • Table 10 Global Neuromodulation Devices Market Outlook, By Chronic Pain (2024-2032) ($MN)
  • Table 11 Global Neuromodulation Devices Market Outlook, By Dystonia (2024-2032) ($MN)
  • Table 12 Global Neuromodulation Devices Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 13 Global Neuromodulation Devices Market Outlook, By Essential Tremor (2024-2032) ($MN)
  • Table 14 Global Neuromodulation Devices Market Outlook, By Heart Failure (2024-2032) ($MN)
  • Table 15 Global Neuromodulation Devices Market Outlook, By Major Depressive Disorder (2024-2032) ($MN)
  • Table 16 Global Neuromodulation Devices Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 17 Global Neuromodulation Devices Market Outlook, By Obsessive-Compulsive Disorder (2024-2032) ($MN)
  • Table 18 Global Neuromodulation Devices Market Outlook, By Overactive Bladder (2024-2032) ($MN)
  • Table 19 Global Neuromodulation Devices Market Outlook, By Sleep Apnea (2024-2032) ($MN)
  • Table 20 Global Neuromodulation Devices Market Outlook, By MRI Compatibility (2024-2032) ($MN)
  • Table 21 Global Neuromodulation Devices Market Outlook, By MRI Compatible (2024-2032) ($MN)
  • Table 22 Global Neuromodulation Devices Market Outlook, By MRI Non-Compatible (2024-2032) ($MN)
  • Table 23 Global Neuromodulation Devices Market Outlook, By Biomaterial (2024-2032) ($MN)
  • Table 24 Global Neuromodulation Devices Market Outlook, By Metallic Biomaterials (2024-2032) ($MN)
  • Table 25 Global Neuromodulation Devices Market Outlook, By Polymeric Biomaterials (2024-2032) ($MN)
  • Table 26 Global Neuromodulation Devices Market Outlook, By Ceramic Biomaterials (2024-2032) ($MN)
  • Table 27 Global Neuromodulation Devices Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Neuromodulation Devices Market Outlook, By Hospital (2024-2032) ($MN)
  • Table 29 Global Neuromodulation Devices Market Outlook, By Neurological Clinics (2024-2032) ($MN)
  • Table 30 Global Neuromodulation Devices Market Outlook, By Home Healthcare (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.